DS 3201

Drug Profile

DS 3201

Alternative Names: DS-3201; DS-3201b

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Inc
  • Class Antineoplastics
  • Mechanism of Action EZH2 enzyme inhibitors; Histone-lysine N-methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 15 Sep 2017 MD Anderson Cancer Center and Daiichi Sankyo plans phase I and phase II trials for Acute myeloid leukemia
  • 15 Sep 2017 MD Anderson Cancer Center and Daiichi Sankyo agree to co-develop DS 3201 for Acute myeloid leukemia
  • 28 Mar 2017 Phase-I clinical trials in Acute myeloid leukaemia and Acute lymphoblastic leukaemia (Second-line therapy or greater, In adults, In the elderly) in USA (PO) (NCT03110354)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top